NeuroOne Medical Technologies Corporation announced the appointment of David Wambeke as Chief Business Officer, with the executive simultaneously purchasing 1,000,000 shares of company stock. The dual announcement signals both strategic leadership expansion and personal investment conviction in the medical technology company's growth trajectory. Wambeke will lead NeuroOne's drug delivery program while working closely with the executive team to advance clinical development and commercialization strategy. His responsibilities include refining product requirements for preclinical and clinical-stage devices, expanding relationships with key opinion leaders, and engaging prospective pharmaceutical partners to maximize the strategic value of the company's emerging drug delivery platform.
David brings a rare combination of public company experience, capital markets expertise, and a demonstrated ability to translate strategic vision into operational and clinical execution, said Dave Rosa, CEO of NeuroOne. The company believes Wambeke will be instrumental in sharpening messaging, deepening investor engagement, and advancing business development activities that support long-term value creation. Wambeke most recently served as Chief Business Officer at DiaMedica Therapeutics, where he led the strategic expansion of the company's lead biologic into preeclampsia. He established and oversaw a first-in-pregnancy Phase 2 clinical trial that delivered positive results and contributed to substantial shareholder value creation. Prior to DiaMedica, he spent approximately 16 years at Craig-Hallum Capital Group in life sciences investment banking, advising public and private healthcare companies on equity financings, M&A, and strategic transactions.
I'm excited to join NeuroOne at such a pivotal moment and to meaningfully align myself with shareholders through my investment, said Wambeke. With four FDA 510(k)-cleared devices and a strategic partnership with Zimmer Biomet, NeuroOne has validated its platform technology and established a strong commercial foundation in epilepsy and trigeminal nerve applications. He noted that greater opportunities lie ahead in basivertebral ablation, drug delivery, and spinal cord stimulation as the company scales commercialization across cleared indications. In conjunction with his appointment, Wambeke purchased 1,000,000 shares of NeuroOne's common stock at a purchase price of $0.6704 per share, representing the closing price of the company's common stock on February 27, 2026.
NeuroOne intends to use the net proceeds from this sale to support ongoing clinical and product development activities, as well as for working capital and general corporate purposes. The shares sold to Wambeke have not been registered under the U.S. Securities Act of 1933, as amended, or any state or other applicable jurisdiction's securities laws. In connection with Wambeke's appointment, the company granted him an inducement stock option to purchase 500,000 shares of common stock of NeuroOne pursuant to the NeuroOne Medical Technologies Corporation 2021 Inducement Plan. The inducement grant was approved by the company's compensation committee of the board of directors and was effective as of Wambeke's first date of employment, March 1, 2026. The stock option has an exercise price of $0.6704 per share, which is equal to the closing price of NeuroOne's common stock on the grant date, and a 10-year term.
NeuroOne Medical Technologies Corporation is a medical technology company focused on improving surgical care options and outcomes for patients suffering from neurological disorders. The company markets a minimally invasive and high-definition/high-precision electrode technology platform with four FDA-cleared product families, including Evo Cortical Electrodes, Evo sEEG Electrodes, OneRF Ablation System (for brain), and OneRF Trigeminal Nerve Ablation System. These solutions offer the potential to reduce hospitalizations and surgical procedures, lower costs, and improve patient outcomes by offering combination diagnostic and therapeutic functions. For more information, visit https://nmtc1.com.
